Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1499251-18-1
Molecular formula
C520H679F21N175O309P43S6
Molecular weight
16248.27 g/mol
Drug class
Antithrombin-directed small interfering RNA (siRNA)RNA interference haemostatic therapy
Mechanism of action
A GalNAc-conjugated siRNA is taken up by hepatocytes and directs RNA-induced silencing complex-mediated degradation of antithrombin mRNA, reducing antithrombin protein and increasing thrombin generation to improve haemostasis.
Indications / reported uses
Routine prophylaxis to prevent or reduce bleeding episodes in adults and paediatric patients aged 12 years and older with haemophilia A or B, with or without factor VIII or IX inhibitors, under the US QFITLIA indication; subcutaneous dosing is monitored using antithrombin activity
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Fitusiran PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fitusiran Permitted Daily Exposure (PDE) report (the Fitusiran PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fitusiran Occupational Exposure Limit (OEL) report (the Fitusiran OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.